Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.51 |
| ▸ | TLR2 | O60603 | 3/20 | 0.50 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.50 |
| ▸ | KLK7 | P49862 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29768865 | 1.00 | KMT2A (0.53) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL24246257 | 1.00 | KMT2A (0.53) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL16870063 | 1.00 | KMT2A (0.53) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL24246233 | 0.98 | KMT2A (0.52) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL999302 | 0.92 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 | |
| SCHEMBL2292778 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL1738182 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL2524769 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL30886226 | 0.92 | MDM2 (0.59) | KMT2AMDM2TLR2TLR1ALDH1A1 | |
| SCHEMBL12040103 | 0.92 | KMT2A (0.58) | KMT2AMDM2TLR2TLR1KLK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416329-A1 | A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2023-12-28 | — | — | US | disclosed |
| WO-2022111713-A9 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2023-07-27 | — | — | WO | disclosed |
| WO-2022111713-A1 | POLYPEPTIDE CONTAINING DISULFIDE BONDS AND CAPABLE OF INHIBITING ACTIVITY OF SERINE PROTEASE, DERIVED HYBRID PEPTIDE THEREOF, AND USE THEREOF | 中国医学科学院药物研究所 | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416329-A1 | A PEPTIDE WITH DISULFIDE BONDS AND INHIBITORY ACTIVITY AGAINST SERINE PROTEASES, DERIVED HYBRID PEPTIDES THEREOF, AND USES THEREOF | VIP, SI, TMPRSS15 | KMT2A 4712/4885MDM2 3001/4885TLR2 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.